Erythromycin base Erythromycin Base
Chemistry and General Charasteristics: Source; produced from a strain of Streptomyces erythraeus.Chemical group: Macrolide group of antibiotic.Chemical name: Erythromycin.Molecular formula: C37H67NO13.Molecular weight: 733.93Antibacterial Activity : Erythromycin is most active in vitro against aerobic gram-positive cocci and bacillis .susceptible strains of S.pyogenes, S.pneumonia, and viridans streptococci have MICs that range from 0.015 to 1 µg/ ml .Gram-positive bacilli also are sensitive to erythromycin , typical MICs are 1 µg/ ml for Clostridium perfringens , from 0.2 to 3 µg/ ml for Corynebacterium diphtheria , and from 0.25 to 4 µg/ ml for listeria monocytogenes. It has modest activity in vitro against gram-negative organisms, including H. influenza ( MIC, 1 to 32 µg/ ml ) and N.meningitdis (MIC, 0.4 to 1.6 µg/ ml ) , and good activity against most strains of N.gonorrhoea (MIC, 012 to 2 µg/ ml ) . Useful antibacterial activity also is observed against pasteurella multocida, Borrelia ssp. and Bordetella pertussis. Macrolides are usually active against M.pneumonia (MIC, 0.004 to 0.02 µg/ ml) and legionella pneumophila (MIC, 0.01 to 2 µg/ ml). Most strains of C.trachomatis are inhibited by 0.06 to 2 µg/ ml of erythromycin. Some of the atypical mycobacteria, including M.scrofulaceum, are sensitive to erythromycin in vitro; M.kansasii and M. avium- intracellulare vary in sensitity. M. fortuitum is resistant , Macrolides have no effect on viruses, yeasts , or fungi. Clinical uses : Erythromycin is the drug of choice in corynebacterial infection (diphtheria, corynebacterial sepsis, erythrasma) ; in respiratory, neonatal, ocular, or genital chlamydial infections; and in treatment of community -acquired pneumonia because its spectrum of activity includes the pneumococcus, mycoplasma, and legionella. Erythromycin Is also useful as a penicillin substitute in penicillin allergic individuals with infections caused by staphylococci (assuming that the isolate is susceptible), streptococci, or pneumococci. Emergence of erythromycin resistance in strains of group A streptococci and pneumococci ( penicillin resistant pneumococciin particular) has made macrolides less attractive as first-line agents for treatment of pharyngitis, skin and soft tissue infections, and pneumonia.Erythromycin has been recommended as prophylaxis against endocarditis during dental procedures in individuals with valvular heart disease, though clindamycin, which is better tolerated, has largely replaced it. Although erythromycin estolate is the best-absorbed salt, it imposes the greatest risk of adverse reactions.Therefore, the stearate or succinate salt may be preferred.Erythromycin as an intermediate for production of : - Erythromycin Ethyl Succinate /propionate /Estolate/Stearate - Azithromycin - Clarithromycin- Roxithromycin- Other macrolides antibiotics This intermediate is produced in Shafa-e-Sari Company in conformity with the latest USP, BP, EP, and IP specifications . General Information : Erythromycin Base is Presented to pharmaceutical companies in order to produce other macrolide APIs such as Erythromycin Ethylsuccinate, Azithromycin, Roxithromycin and Clarythromycin. The advantages of Shafa's Erythromycin in comparison with the competitors are : - Unique purity quality- Halal Certification awarded from Islamic Chamber Research & Information Center (ICRIC) - Production under GMP certificate (Good Manufacturing Practice) from Ministry of Health- Production under ISO 9001 certificate Opportunities for Cooperation :Shafa Co. welcomes cooperation with other companies in the field of joint production and marketing.